Ella W Mathews,Sydney R Coffey,Annette Gaertner,Jillian Belgrad,Robert M Bragg,Daniel O'Reilly,Jeffrey P Cantle,Cassandra McHugh,Ashley Summers,Joachim Fentz,Tom Schwagarus,Antje Cornelius,Ioannis Lingos,Zoe Burch,Marina Kovalenko,Marissa A Andrew,C. Frank Bennett,Holly Kordasiewicz,Deanna M Marchionini,Hilary Wilkinson,Thomas F Vogt,Richard M Pinto,Anastasia Khvorova,David Howland,Vanessa Wheeler,Jeffrey Brian Carroll

Abstract:Huntington's disease (HD) arises from a CAG expansion in the huntingtin (HTT) gene beyond a critical threshold. A major thrust of current HD therapeutic development is lowering levels of mutant HTT mRNA (mHTT) and protein (mHTT) with the aim of reducing the toxicity of these product(s). Human genetic data also support a key role for somatic instability (SI) in HTT's CAG repeat -- whereby it lengthens with age in specific somatic cell types -- as a key driver of age of motor dysfunction onset. Thus, an attractive HD therapy would address both mHTT toxicity and SI, but to date the relationship between SI and HTT lowering remains unexplored. Here, we investigated multiple therapeutically-relevant HTT-lowering modalities to establish the relationship between HTT lowering and SI in HD knock-in mice. We find that repressing transcription of mutant Htt (mHtt) provides robust protection from SI, using diverse genetic and pharmacological approaches (antisense oligonucleotides, CRISPR-Cas9 genome editing, the Lac repressor, and virally delivered zinc finger transcriptional repressor proteins, ZFPs). However, we find that small interfering RNA (siRNA), a potent HTT-lowering treatment, lowers HTT levels without influencing SI and that SI is also normal in mice lacking 50% of total HTT levels, suggesting HTT levels, per se, do not modulate SI in trans. Remarkably, modified ZFPs that bind the mHtt locus, but lack a repressive domain, robustly protect from SI, despite not reducing HTT mRNA or protein levels. These results have important therapeutic implications in HD, as they suggest that DNA-targeted HTT-lowering treatments may have significant advantages compared to other HTT-lowering approaches, and that interaction of a DNA-binding protein and HTT's CAG repeats may provide protection from SI while sparing HTT expression.

Nuclear translocation of STAT5 initiates iron overload in huntington's disease by up-regulating IRP1 expression

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

Essential sequence of the N-terminal cytoplasmic localization-related domain of huntingtin and its effect on huntingtin aggregates

Soluble N-terminal Fragment of Mutant Huntingtin Protein Impairs Mitochondrial Axonal Transport in Cultured Hippocampal Neurons.

PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD)

Nucleolar stress controls mutant Huntington toxicity and monitors Huntington’s disease progression

Nuclear Translocation of AMPK-α1 Potentiates Striatal Neurodegeneration in Huntington’s Disease

Mutant Huntingtin stalls ribosomes and represses protein synthesis in a cellular model of Huntington disease

Accumulation of Endogenous Mutant Huntingtin in Astrocytes Exacerbates Neuropathology of Huntington Disease in Mice

Pathogenic TDP‐43 accelerates the generation of toxic exon1 HTT in Huntington's disease knock‐in mice

Effects of Exogenous Nub1 Expression in the Striatum of Hdq175/Q7 Mice

A Striatal-Enriched Intronic GPCR Modulates Huntingtin Levels and Toxicity

Aberrant Rab11-Dependent Trafficking of the Neuronal Glutamate Transporter EAAC1 Causes Oxidative Stress and Cell Death in Huntington's Disease

Compromised retinoic acid receptor beta (RARβ) accelerates the onset of motor, cellular and molecular abnormalities in mouse model of Huntington’s disease

Elevated NADPH Oxidase Activity Contributes to Oxidative Stress and Cell Death in Huntington's Disease.

HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice

Mitochondrial HSF1 triggers mitochondrial dysfunction and neurodegeneration in Huntington's disease

Dysregulation of C/EBPalpha by Mutant Huntingtin Causes the Urea Cycle Deficiency in Huntington's Disease.

Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington's disease

Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding